A letter or commentary responding to the bremelanotide dose-finding phase 2b trial (PMID 27181790). Provides critical analysis or additional perspectives on the trial design, efficacy data interpretation, or the meaningfulness of the reported outcomes for clinical practice.
Seftel, Allen D